Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China

doi:10.1111/1759-7714.14274

HFCAS OpenIR

	Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China
	Shi, Yuequan 1; Fang, Jian 2; Zhou, Chengzhi 3; Liu, Anwen 4; Wang, Yan 5; Meng, Qingwei 6; Ding, Cuimin 7; Ai, Bin 8; Gu, Yangchun 9; Yao, Yu 10; Sun, Hong 10; Guo, Hui 10; Zhang, Cuiying 11; Song, Xia 12; Li, Junling 5; Xu, Bei 13; Han, Zhiqiang 14; Song, Meijun 15; Tang, Tingyu 16; Chen, Peifeng 17; Lu, Hongmin 18; Shui, Yongjie 19; Lou, Guangyuan 20; Zhang, Dongming 1; Liu, Jia 1; Liu, Xiaoyan 1; Liu, Xiangning 1; Gao, Xiaoxing 1; Zhou, Qing 1; Chen, Minjiang 1; Zhao, Jing 1; Zhong, Wei 1; Xu, Yan 1; Wang, Mengzhao 1
	2021-12-21
发表期刊	THORACIC CANCER
ISSN	1759-7706
通讯作者	Wang, Mengzhao(mengzhaowang@sina.com)
摘要	Background Immune checkpoint inhibitors (ICIs) are the standard treatment for advanced lung cancer, but immune-related adverse events (irAEs) remain poorly understood, especially in a real-world setting. Methods A multicenter observational study was conducted. Medical records of lung cancer patients treated with ICIs at 26 hospitals from January 1, 2015, to February 28, 2021, were retrieved. Types of ICIs included antiprogrammed cell death 1 or antiprogrammed cell death ligand 1 (PD-L1) monotherapy, anticytotoxic T-lymphocyte antigen-4 monotherapy, or combination therapy. Results In total, 1905 patients with advanced lung cancer were evaluated. The median age was 63 (range 28-87) years, and the male/female ratio was 3.1:1 (1442/463). The primary histological subtype was adenocarcinoma (915). A total of 26.9% (512/1905) of the patients developed 671 irAEs, and 5.8% (110/1905) developed 120 grade 3-5 irAEs. Median duration from ICI initiation to irAEs onset was 56 (range 0-1160) days. The most common irAEs were thyroid dysfunction (7.2%, 138/1905), pneumonitis (6.5%, 124/1905), and dermatological toxicities (6.0%, 115/1905). A total of 162 irAEs were treated with steroids and 11 irAEs led to death. Patients with positive PD-L1 expression (>= 1%) and who received first-line ICI treatment developed more irAEs. Patients who developed irAEs had a better disease control rate (DCR, 71.3% [365/512] vs. 56.0% [780/1145]; p < 0.001). Conclusions The incidence rate of irAEs was 26.9% in a real-world setting. IrAEs might be related to a better DCR, but clinicians should be more aware of irAE recognition and management in clinical practice.
关键词	advanced lung cancer immune checkpoint inhibitors immune-related adverse events real-world data
DOI	10.1111/1759-7714.14274
关键词[WOS]	EFFICACY ; PEMBROLIZUMAB ; IMMUNOTHERAPY ; CHEMOTHERAPY ; NIVOLUMAB ; OUTCOMES
收录类别	SCI
语种	英语
资助项目	Merk Co., Ltd.
项目资助者	Merk Co., Ltd.
WOS研究方向	Oncology ; Respiratory System
WOS类目	Oncology ; Respiratory System
WOS记录号	WOS:000732478600001
出版者	WILEY
引用统计	被引频次：19[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/126989
专题	中国科学院合肥物质科学研究院
通讯作者	Wang, Mengzhao
作者单位	1.Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Resp & Crit Care Med, Beijing 100730, Peoples R China 2.Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Dept Thorac Oncol 2, Minist Educ Beijing, Beijing, Peoples R China 3.Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Hlth, State Key Lab Resp Dis,Natl Clin Res Ctr Resp Dis, Guangzhou, Peoples R China 4.Nanchang Univ, Affiliated Hosp 2, Dept Oncol, Nanchang, Jiangxi, Peoples R China 5.Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Dept Med Oncol,Natl Canc Ctr, Beijing, Peoples R China 6.Harbin Med Univ, Dept Med Oncol, Canc Hosp, Harbin, Peoples R China 7.Hebei Med Univ, Dept Resp Med, Hosp 4, Shijiazhuang, Hebei, Peoples R China 8.Chinese Acad Med Sci, Beijing Hosp, Natl Ctr Gerontol, Inst Geriatr Med,Dept Med Oncol, Beijing, Peoples R China 9.Peking Univ Third Hosp, Dept Med Oncol & Radiat Sickness, Beijing, Peoples R China 10.Xi An Jiao Tong Univ, Dept Med Oncol, Affiliated Hosp 1, Xian, Peoples R China 11.Peoples Hosp, Canc Ctr, Hohhot, Peoples R China 12.Shanxi Prov Canc Hosp, Dept Resp Med, Taiyuan, Peoples R China 13.Fudan Univ, Dept Med Oncol, Zhongshan Hosp, Shanghai, Peoples R China 14.Quzhou Peoples Hosp, Dept Resp & Crit Care Med, Quzhou, Zhejiang, Peoples R China 15.Zhejiang Prov Peoples Hosp, Dept Resp Med, Hangzhou, Zhejiang, Peoples R China 16.Zhejiang Univ, Affiliated Zhejiang Hosp, Dept Resp Med, Sch Med, Hangzhou, Zhejiang, Peoples R China 17.Zhuji Peoples Hosp, Dept Resp Med & Crit Care Med, Zhuji, Zhejiang, Peoples R China 18.Shanghai Jiao Tong Univ, Renji Hosp, Dept Oncol, Sch Med, Shanghai, Peoples R China 19.Zhejiang Univ, Affiliated Hosp 2, Dept Radiat Oncol, Sch Med, Hangzhou, Peoples R China 20.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Med Oncol, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Shi, Yuequan,Fang, Jian,Zhou, Chengzhi,et al. Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China[J]. THORACIC CANCER,2021.
APA	Shi, Yuequan.,Fang, Jian.,Zhou, Chengzhi.,Liu, Anwen.,Wang, Yan.,...&Wang, Mengzhao.(2021).Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China.THORACIC CANCER.
MLA	Shi, Yuequan,et al."Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China".THORACIC CANCER (2021).